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OPINION
A biomarker approach to syndrome‑based 
treatment of severe childhood illness 
in malaria‑endemic areas
Hans Ackerman1 and Climent Casals‑Pascual2,3* 
Abstract 
This opinion article deals with the diagnostic clinical challenges faced by clinicians or health care workers in malaria‑
endemic areas when a severely sick child presents to the clinic with fever, coma or respiratory distress. Indeed, the 
coexistence of malaria with other severe infections like meningitis, invasive bacterial infection or pneumonia makes 
appropriate treatment allocation a matter of life and death. The use of biomarkers has been proposed as a potential 
solution to this problem. The arrival of high‑throughput technologies allowed thousands of molecules (transcripts, 
proteins and metabolites) to be been screened in clinical samples from large cohorts of well/characterised patients. 
The major aim of these studies was to identify biomarkers that inform important decisions: should this child be 
referred to hospital? Should antibiotics, anti‑malarials, or both, be administered? There is a large discrepancy between 
the number of biomarker discovery studies published and the number of biomarkers that have been clinically vali‑
dated, let alone implemented. This article reflects on the many opportunities and obstacles encountered in biomarker 
research in malaria‑endemic areas.
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Background: the clinical challenge
In malaria-endemic areas, the coexistence of Plasmo-
dium falciparum parasitaemia with other severe diseases 
like pneumonia, bacteraemia and meningitis complicates 
the definitive diagnosis of severe malaria [1–4]. Notably, 
when a critically ill child presents with fever, impaired 
consciousness and P. falciparum on the blood smear, 
severe malaria might not be the primary diagnosis—
especially in regions where asymptomatic parasitaemia 
is common. To further complicate the picture, malaria 
infection predisposes to bacterial infection and may co-
occur with more than half of all cases of bacteraemia in 
malaria-endemic areas [5]. The presence of malaria par-
asites or malarial antigens in the child’s blood does not 
justify withholding empirical parenteral antibiotics [6]. 
This diagnostic challenge can be further aggravated in 
settings where medical training or laboratory facilities 
are inadequate.
The identification and validation of novel biomarkers 
with high sensitivity and specificity for severe malaria 
(SM) may contribute to the development and implemen-
tation of new diagnostic tools, for example, in a rapid 
diagnostic test (RDT) format that can optimize treatment 
allocation and reduce mortality from severe childhood 
illness.
The current case definition of severe malaria proposed 
by the World Health Organization (WHO) is based on 
the observation of parasites on a blood smear accom-
panied by one or more severe clinical manifestations, 
namely prostration, impaired consciousness, respiratory 
distress, multiple convulsions, severe anaemia, jaundice 
or shock [7]. This definition is pragmatic and rightly pri-
oritizes sensitivity over specificity due to the high risk 
of death associated with a missed diagnosis or delayed 
treatment of P. falciparum infection. Rapid identification 
of danger signs by specifically trained non-medical per-
sonnel helps to identify those children with malaria at the 
highest risk of dying. However, despite improved access 
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to treatment and declining trends of malaria observed 
worldwide [8, 9], the number of deaths remain high 
(approximately 450,000 yearly [10]), mostly in young chil-
dren from sub-Saharan Africa.
What are the limitations of a highly sensitive 
but poorly specific case definition?
For any clinical condition, the major consequence of a 
poorly specific case definition is the administration of 
unnecessary treatment and, in the context of malaria, the 
potential for accelerated development of parasite drug 
resistance. According to the WHO recommendation, 
the administration of anti-malarials in malaria endemic 
areas should only be used after the presence of parasites 
has been confirmed through visualization of the para-
site P. falciparum on a Giemsa-stained thick smear (gold 
standard) or more frequently, through indirect methods, 
such as the detection of parasite proteins using a RDT. In 
practice, these guidelines are only partially followed, even 
when RDTs are available [11].
Diagnostic specificity is important for appropriate 
treatment allocation
The diagnostic complexity of severe malaria is a reflec-
tion of its pathophysiological complexity, illustrated by 
three potentially overlapping clinical syndromes of SM: 
cerebral malaria, respiratory distress and severe malarial 
anaemia [7, 12]. The majority of deaths from SM occur 
in children presenting with cerebral malaria or respira-
tory distress, and those presenting with more than one 
syndrome of SM have an even greater risk of death. In 
malaria-endemic regions, severe malaria complicated by 
impaired consciousness or respiratory distress may be 
indistinguishable from life-threatening illnesses such as 
meningitis or pneumonia. In this context, a highly sensi-
tive but poorly specific definition of severe malaria may 
have deleterious consequences if empirical treatment for 
alternative diagnoses is not provided.
How can we improve our ability to discriminate SM 
from other clinical conditions?
The use of biomarkers has been proposed to facilitate a 
syndrome-based management approach. In a hypotheti-
cal scenario, in a malaria-endemic area a drop of blood 
could be obtained from a child presenting with fever and 
respiratory distress and analysed with a panel of bio-
markers that have the ability to inform a clinical deci-
sion (see Box  1): to administer antibiotics (pneumonia), 
anti-malarials (P. falciparum or non-falciparum malaria), 
administration of antibiotics and anti-malarials, to indi-
cate urgent referral to hospital [13–15], or send the child 
home with symptomatic treatment or no treatment at 
all (non-severe respiratory virus, or common cold). To 
achieve this, the biomarker panel should determine the 
presence or absence of the common critical illness in the 
community, namely severe malaria, bacterial infection, or 
viral infection.
Which biomarkers should be used? And do these bio-
markers exist? The quest to identify the perfect panel of 
biomarkers to inform clinical decisions was galvanized by 
the advent of high-throughput “omics” technologies (see 
Box 2). When these powerful technologies became more 
popular and affordable, clinical samples from well-char-
acterized cohorts of patients were screened for potential 
biomarkers. Exhaustive lists of genes, mRNA and pro-
teins were produced and candidate markers identified. 
Unfortunately, difficulties in candidate selection and the 
need for thorough clinical validation mean that very few 
putative biomarkers have been clinically implemented.
Machine‑learning or machine‑teaching?
Candidate selection is problematic. The identification 
of a minimal set of informative biomarkers relies heav-
ily on machine-learning algorithms. Briefly, an algo-
rithm is given two phenotypes, i.e. mild malaria versus 
severe malaria, and it identifies discriminating features 
from a broad dataset (e.g., genes, transcripts, proteins 
or metabolites). Some of these features are then selected 
and tested in silico on a different set of patients not used 
in the training phase. In a successful test, the algorithm 
will correctly assign the unknown patients to the correct 
clinical phenotype based on a minimal set of informative 
features. The list of features can vary in length depending 
on the type of biomarker and the study design. In pro-
teomic and transcriptomic studies, it is not uncommon 
to identify hundreds of discriminant features. The more 
distinct the clinical phenotypes analysed, the longer the 
list of discriminating biomarkers. It is important that 
the study design mirror the diagnostic challenge to be 
resolved. A study design that includes only extreme 
phenotypes (for example, severe malaria versus healthy 
controls) may not yield relevant information and the can-
didate biomarker(s) might just be expensive alternatives 
to measuring axillary temperature. Instead, a more useful 
approach might be to compare severe malaria versus mild 
malaria, or severe malaria versus pneumonia, to identify 
biomarkers that inform clinical decision-making.
How much evidence is sufficient to validate 
candidate biomarkers?
Biomarker validation is the most expensive, risky and 
time-consuming phase of biomarker research and rarely 
pursued by investigators unless the results of the dis-
covery phase are very promising. Here, the investigators 
are expected to accurately quantify the candidate bio-
markers in biofluids and produce estimates of sensitivity, 
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specificity, positive- and negative-predictive values to 
inform the research community about the potential 
clinical impact of the candidate biomarker(s). Next, 
independent, adequately powered, clinical studies will 
be required, followed by at least one larger, ambitious 
prospective study where clinical decisions are based on 
the biomarker concentration and patient outcomes are 
compared to those achieved with standard practice. This 
phase also depends on the existence of suitable intellec-
tual property and the availability of a diagnostic prod-
uct or a prototype to measure the biomarker. In reality, 
few examples of successful biomarkers have successfully 
emerged from this process. Even when efficacy is dem-
onstrated, cost-efficacy may prevent incorporation of a 
biomarker into routine practice. Procalcitonin (PCT), a 
biomarker that detects bacterial infection, can be used to 
illustrate this point (reviewed in [16]). A large number of 
adequately powered studies have shown the high efficacy 
of PCT to identify bacterial infection, including a clinical 
trial conducted to ascertain the value of this molecule to 
successfully indicate antibiotic treatment in critical care 
patients [17]. However, when it comes to clinical use, 
the cost of measuring PCT could be 10–20 times higher 
than a less biomarkers such as C-reactive protein. How 
do you determine when the increased performance of a 
biomarker justifies the increased cost? Attempts at cost-
effectiveness modelling have not resolved this issue. In 
the case of malaria, the cost of an optimal panel of bio-
markers will have to be affordable, and certainly not cost 
more than the treatments it saves, if it is to be imple-
mented in practice.
A closer look at cerebral malaria
Not all good biomarkers are molecules. A working defini-
tion of “biomarker” (short for “biological marker”) refers 
to objective indications of a medical state observed from 
outside the patient [18]. Although the term “biomarker” 
has evolved to become equivalent to molecular marker, a 
clinical sign can be also labelled as biomarker if it can be 
quantified accurately and reproducibly.
Cerebral malaria (CM) provides a good example. 
CM is classically defined in children as a deep level of 
unconsciousness (inability to localize a painful stimu-
lus) in the presence of asexual parasitaemia, after the 
correction of hypoglycaemia and exclusion of other 
encephalopathies, especially bacterial meningitis and 
locally prevalent viral encephalitis [19]. Notably, this 
definition underlines diagnostic specificity by empha-
sizing the need to rule out other conditions. It is not 
always trivial to discriminate cerebral malaria from 
meningitis as both conditions share many clinical fea-
tures [3, 20]. Moreover, post-mortem studies have 
shown that even when strict clinical criteria are used to 
diagnose CM, 23% of cases were found on post-mortem 
examination to have died from other causes [21–23]. 
Interestingly, this and other studies describe specific 
retinal changes as the only clinical sign that discrimi-
nates malarial from non-malarial causes of coma [22, 
23]. While there are logistical impediments to routine 
implementation of fundoscopy in hospitals and clinics, 
this specific clinical sign offers an opportunity to better 
define cerebral malaria for molecular biomarker discov-
ery studies. Indeed, angiopoietin-2 has been proposed 
as a candidate biomarker to discriminate CM from 
other causes of coma as this biomarker appears to be 
closely associated with the retinal changes of CM in 
Malawian children [24].
Molecular biomarkers that discriminate SM syndromes 
from other infections are urgently needed. Although 
some of the biomarker research show promise (reviewed 
in [25]), a major bottleneck to implementation remains 
the development of effective, rapid, affordable, easy-to-
use diagnostic tools that should ideally combine patho-
gen and host-derived biomarkers. Syndrome-based 
diagnostics may well replace pathogen-based diagnostics 
in the future. Academy-industry partnerships will be nec-
essary to shepherd promising biomarkers from discovery 
through implementation.
Box 1. Severe malaria versus bacterial 
pneumonia. Some progress
Respiratory distress is a common presentation of SM, 
but practically impossible to distinguish from severe 
pneumonia [4, 26–28]. Critically, the clinical manage-
ment is different for both conditions. It is, therefore, 
crucial to develop new tools to assist health workers to 
effectively identify and refer to hospital those children 
with malaria or pneumonia who are at the highest risk 
of dying.
In 2014, Huang and colleagues conducted a prot-
eomic discovery study in 390 Gambian children and 
identified a panel of two biomarkers (haptoglobin 
and lipocalin-2) to discriminate acute respiratory 
infection from severe malaria with respiratory distress 
[29]. These proteins were further validated in a study 
of 293 Kenyan children. The combination of hapto-
globin and lipocalin-2 discriminated acute respiratory 
distress from malaria with high sensitivity and speci-
ficity (area under the ROC curve of 99% in Gambian 
children and 82% in Kenyan children). More recently, 
a study conducted in Mozambique [30], used a multi-
plex immunoassay panel of 56 proteins, to find that the 
combination of three proteins (haptoglobin, tumour 
necrosis factor receptor 2 or IL-10, and tissue 
inhibitor of metalloproteinases-1) discriminated 
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bacterial diagnosis from malaria with high sensitivity 
and specificity (96 and 86%, respectively).
Why is haptoglobin a good biomarker to discrimi-
nate malaria from bacterial infection in children with 
respiratory distress?
Haptoglobin is a highly abundant plasma protein. 
During acute inflammatory response, haptoglobin is 
further secreted by neutrophils in response to infec-
tion [31]. However, the primary function of hapto-
globin is to bind free-circulating haemoglobin and 
prevent haemoglobin-induced oxidative cell damage. 
These high-affinity complexes are later removed by 
CD163 scavenger receptor on macrophages that will 
eliminate this complex (and recycle iron) through 
endocytosis and subsequent intracellular degradation 
[32]. Acute malaria infection is accompanied by some 
degree of haemolysis, and the drive to increase hapto-
globin as part of the inflammatory response is clearly 
offset by haemolysis, which drives haptoglobin con-
centration towards depletion. This polarized response 
(increased in bacterial infection and decreased in 
malaria) produces a much sought after “curtain effect” 
that pulls the two conditions apart by quantifying a 
single biomarker.
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